GHK-Cu is a commonly searched research compound, and it also appears as a component of multi-peptide blends. The questions to settle before ordering are the familiar ones: what is it, what does its documentation establish, and what is the regulatory context in Canada. This is a source-based summary. It is not a guide to any use, not a claim that GHK-Cu is an authorized drug or suitable for human use, and not legal or medical advice.

Identity starts with the named compound

GHK-Cu is a naturally occurring copper complex of the tripeptide glycyl-L-histidyl-L-lysine (Gly-His-Lys) bound to copper(II), with the copper-complex molecular formula C14H22CuN6O4. It is present in human plasma — where reported levels decline with age — as well as in saliva and urine, and the synthetic form is a well-known cosmetic ingredient listed under the INCI name Copper tripeptide-1. Those are identity facts: a procurement record should still begin with the compound name, the copper-complex identity, the selected strength, and the lot, so a receiving laboratory can reconcile what was ordered against the label and the source document. None of it verifies biological activity or authorizes a route of use.

Research status and an important distinction

That GHK-Cu occurs naturally and is used as a cosmetic ingredient does not make an injectable research material an authorized drug. The two are different things: a cosmetic-ingredient identity, or a molecule’s natural presence in the body, says nothing about whether a lyophilized, reconstituted-for-injection research preparation has been assessed or authorized by a regulator. This article makes no claim about effects and is not a summary of research outcomes.

Canadian regulatory context

Health Canada’s April 2026 public advisory on unauthorized injectable peptides names GHK-Cu among the products it identifies, and states that unauthorized drug products are illegal in Canada and have not been assessed for safety, efficacy, and quality by Health Canada. The advisory is explicit that a “research use only” label “does not make these products legal or exempt from regulatory requirements.” Vitatide’s research-use wording should be read the same way — a use boundary, not a claim of regulatory authorization — and determining whether a given procurement, possession, import, or use complies with applicable requirements remains the purchaser’s and the receiving laboratory’s responsibility.

Read the Health Canada public advisory

What a CoA can and cannot establish

A lot-linked Certificate of Analysis can report measurements such as chromatographic area percentage, observed mass, or other tests performed by the issuing laboratory, and its scope is limited to the sample, methods, and results stated on that document. Because GHK-Cu is a copper complex rather than a single sequence, its documentation should make the copper-complex identity clear. The checks are otherwise the same:

  • Match the compound, lot, and certificate identifier.
  • Read the method and the actual measured value.
  • Separate chromatographic purity from identity and potency.
  • Do not treat a CoA as regulatory approval, sterility assurance, or a substitute for an end laboratory’s validated controls unless the document expressly supports that conclusion.

Procurement boundary for Canadian laboratories

Before ordering, review the canonical product page, the posted source record, destination restrictions, and the Research-Use-Only Acknowledgement. After receipt, identity reconciliation, storage, preparation, assay design, waste handling, and chain-of-custody remain the receiving laboratory’s responsibility.

For laboratory research use only. Not for human consumption, diagnostic, or therapeutic use. This article summarizes public regulatory and reference sources and is not legal or medical advice.